



Healionics' Subsidiary iSTAR Medical Selected to Present at EuroMedtech 2011 in Turin, Italy

Seattle, WA (April 20, 2011) — Michel Alvarez, CEO of Healionics Corporation, has been selected to present iSTAR Medical to the medical technology community at EuroMedtech 2011, in Turin, Italy on May 16-17.

“The two-day conference provides us with an opportunity to report on iSTAR Medical’s progress over the past months to our European investment community” says Alvarez.

iSTAR Medical was created in Belgium in late 2010 with financing support from the Region Wallone government to develop its first device – STARflo™ Glaucoma Implant made from Healionics’ innovative STAR® biomaterial under exclusive agreement.

Glaucoma is the second leading cause of blindness afflicting approximately 70 million people worldwide. The global market for glaucoma management solutions is \$4.5 billion per year.

More information about EuroMedtech 2011 can be found at <http://www.ebdgroup.com/emt/>.

About Healionics Corporation

Healionics is a biomaterials technology company whose flagship STAR® Biomaterial aims to solve the historic “device-to-tissue” interface problem of long-term medical implants. Better healing and functioning implants are key to improving patient well-being while reducing the ballooning \$50 billion per year in global healthcare costs attributed to implant failures. STAR Biomaterial has shown promising results in reducing fibrosis, enhancing biointegration, and resisting infection, addressing several common causes for failure of long-term implants. www.healionics.com

About iSTAR Medical

iSTAR Medical SA is a Belgium-based spinout of Healionics Corporation. Its mission is to improve the lives of patients suffering from eye diseases and disorders. iSTAR’s initial focus is to develop ophthalmic implants made from STAR Biomaterial for treating glaucoma and corneal blindness. www.istarmed.com

###

Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com